Taro Pharmaceutical Industries (TARO)
(Delayed Data from NYSE)
$42.40 USD
-0.08 (-0.19%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $42.39 -0.01 (-0.02%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Taro Pharmaceutical Industries Ltd falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | NA | 573 | 561 | 549 | 645 |
Cost Of Goods | NA | 305 | 268 | 252 | 245 |
Gross Profit | NA | 268 | 293 | 297 | 400 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 251 | 230 | 710 | 153 |
Income After Depreciation & Amortization | 0 | 18 | 63 | -414 | 247 |
Non-Operating Income | NA | 21 | 14 | 23 | 52 |
Interest Expense | NA | 0 | 0 | 0 | 0 |
Pretax Income | NA | 38 | 78 | -391 | 298 |
Income Taxes | NA | 13 | 20 | 10 | 53 |
Minority Interest | NA | 0 | 0 | -14 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | 25 | 58 | -401 | 245 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | 25 | 58 | -387 | 244 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | 58 | 89 | -390 | 268 |
Depreciation & Amortization (Cash Flow) | NA | 40 | 26 | 24 | 21 |
Income After Depreciation & Amortization | 0 | 18 | 63 | -414 | 247 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | NA | 37.59 | 37.64 | 38.21 | 38.46 |
Diluted EPS Before Non-Recurring Items | NA | 0.68 | 3.36 | 3.70 | 6.35 |
Diluted Net EPS (GAAP) | NA | 0.68 | 1.55 | -10.12 | 6.35 |
Fiscal Year end for Taro Pharmaceutical Industries Ltd falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 157.15 | 148.20 | 158.89 | 146.59 |
Cost Of Goods | NA | 77.26 | 74.60 | 94.81 | 70.88 |
Gross Profit | NA | 79.88 | 73.60 | 64.08 | 75.71 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 64.00 | 68.87 | 72.01 | 66.44 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 15.88 | 4.73 | -7.93 | 9.27 |
Non-Operating Income | NA | 17.46 | 12.92 | 13.36 | 8.63 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | 33.34 | 17.66 | 5.44 | 17.90 |
Income Taxes | NA | 13.14 | 9.11 | -4.59 | 10.99 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 20.21 | 8.55 | 10.03 | 6.91 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 20.21 | 8.55 | 10.03 | 6.91 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 37.59 | 37.59 | 37.59 | 37.59 |
Diluted EPS Before Non-Recurring Items | NA | 0.56 | 0.38 | 0.40 | 0.18 |
Diluted Net EPS (GAAP) | NA | 0.54 | 0.23 | 0.27 | 0.19 |